Participate in Research

Research studies help find new methods for diagnosing, treating, managing, and preventing Crohn's disease and ulcerative colitis. Even the most promising scientific findings must first be proven to be safe and effective before they can be used in the management of inflammatory bowel disease (IBD).

If you are interested in learning more about participating in a research study or clinical trial, speak with your doctor.

For Researchers recruiting patients for study participation

Are you a researcher looking to promote your research study among patients with Crohn's or colitis? Crohn’s and Colitis Canada currently promotes studies conducted by scientists affiliated with academic institutions who have demonstrated proof of ethics approval. Promotion will be via our website or social media accounts (Twitter, Instagram, Facebook, and LinkedIn). At this time, we cannot promote research study recruitment via email. 

To submit a request to have your study promoted by Crohn's and Colitis Canada, complete the online form HERE. Our research programs team will review your request and connect with you about next steps.

Participate in Research icons

Active studies recruiting participants: 

  • What is this Study About?

    The IMAGINE Network is currently recruiting healthy individuals along with persons with inMammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Our goal is to recruit 8,000 subjects and will study how three important variables (genes, diet and mental health) impact the gut microbiome and, in turn, how together they impact the disease course.

    Who can Participate?

    Adults or children with IBD or IBS, or healthy subjects

    This study has been approved by the Hamilton Integrated Research Ethics Board (REB #3000).

    Primary Contact
    Aida Fernandes

    Principal Investigator
    Paul Moayyedi
    McMaster University
  • What is this Study About?

    The goal of our study is to collect inflammatory bowel disease (IBD) patients' opinions on the digital health tools available ot them. Your opinion will help us develop tools that better suit the needs of IBD patients in Alberta.

    Who can Participate?

    Adults aged 18+ who have IBD and reside in Alberta.

    Your Role in this Study

    Participants who complete the survey can express their interest in participating in a follow-up interview. Participants who complete the interview will recieve a $25 honorarium for their time.

    You can complete the anonymous 5-minute survey here:

    This study has been reviewed for adherence to ethical guidelines by the University of Alberta Health Research Ethics Board (Pro00133852).

    Primary Contact
    Somayeh Raeisdana

    Principal Investigator
    Dr. Karen Wong
    University of Alberta
  • What is this Study About?

    We invite you to participate in a research project in a project which aims to understand Canadians’ experience of care provided to people prescribed specialty medicines.

    Many drug manufacturers now offer patient support programs to provide financial support, education, or care coordination to people prescribed their drugs.

    Who can Participate?

    People living across Canada and across a range of urban, suburban, rural, and remote settings, who are prescribed a medication that they take by injection or intravenous infusion. Participants are invited to have a support person or caregiver join the interview, or to permit us to interview them separately.

    Your Role in this Study

    We will be conducting 1-hour virtual interviews with Canadians who are prescribed a medication that requires infusion, self-injection, or otherwise requires specialized supports. We are interested to learn more about how you accessed these supports and your experience of medication-related care.

    If eligible, we will provide you further details about the date and time. The interview will last up to an hour and will explore your experiences with these services. A $50 gift card will be provided in acknowledgement of your time.

    This study, led by Dr. Quinn Grundy at the University of Toronto at the Faculty of Nursing is supported by the government of Canada's Canadian Institutes of Health Research and the Social Sciences and Humanities Research Council.

    If you know anyone who might be interested in participating, feel free to share this invitation with anyone who might have relevant experiences.

    This study has been approved by the University of Toronto's Research Ethics Board (REB #45085).

    Primary Contact
    Quinn Grundy

    Principal Investigator
    Quinn Grundy
    University of Toronto
  • What is this Study About?

    Inflammatory bowel disease (IBD) is a lifelong chronic inflammatory condition that requires ongoing interactions with the healthcare system. However, not everyone may feel safe accessing and receiving IBD-related care or communicating openly with their provider. One such marginalized group of individuals who may not feel comfortable are those who identify as transgender or gender diverse.

    The purpose of this multidisciplinary, patient-oriented, pilot qualitative study is to explore care experiences and expectations in transgender and gender diverse individuals who live with IBD.

    Who can Participate?

    Individuals who are Canadian adults 18 years or older; are diagnosed with Crohn's disease or ulcerative colitis; and who self-identify as transgender or gender diverse are invited to participate.

    Your Role in this Study

    Individuals will have an opportunity to be interviewed virtually (via Zoom) either individually or in a group setting.

    The goal of this project is to allow individuals a supportive place to share their experiences regarding accessing and receiving IBD-related care and to understand what strategies would encourage a comfortable and safe IBD-related healthcare space for individuals who are transgender or gender diverse.

    This study has been approved by the University of Saskatchewan's Research Ethics Board (REB #4455).

    Primary Contact
    Natasha Tooke

    Principal Investigator
    Noelle Rohatinsky
    University of Saskatchewan
  • What is this Study About?

    Fibrosis (thickening and scarring) within the intestinal tract is common in patients with Crohn’s Disease. There are currently no approved therapies for treating fibrosis in the intestinal tract and therefore there is an urgent need for safe and effective antifibrotic therapies in fibrostenotic Crohn’s Disease. This oral therapy is hoping to be able to change that and help relieve stricturing Crohn’s Disease without having patients undergo surgery.

    Who can Participate?

    Patients age 18 and older with stricturing Crohn’s Disease. Patients must be living in Toronto, ON and able to travel.

    Your Role in this Study

    This study lasts for about 16 weeks and consist of a screening period, treatment period and safety follow-up.

    Screening period (can last up to 35 days): Participants will come on site to go over their medical history, current and past medications, do an ECG (electrocardiogram), and colonoscopy. Patients will also go off site to Mount Sinai Hospital to complete an MRI for the intestines and an echocardiogram

    Treatment period (last 12 weeks): Participants will come on site every 2-4 weeks for a doctor and nurse to do an assessment on their health and do an ECG. Participants will also be given study medication. At the final 12 week visit, participants will undergo a colonoscopy and ECG on site and an MRI and echocardiogram at Mount Sinai Hospital again.

    This study has been approved by the Advarra Research Ethics Board (REB #SSU00224057).

    Primary Contact
    Mindy Xu

    Principal Investigator
    Dr. Mark Silverberg
    TIDHI Innovation Inc.
  • What is this study about? 

    The global prevalence of IBD continues to rise. Despite substantial advances in therapeutics, IBD has no cure, leads to reduced quality of life, and causes significant personal and societal burden.

    We need to improve treatment of IBD and continue to search for a cure. Simultaneously, prediction and prevention of new cases is a critical goal.

    Over the past few years, research into the pre-diagnostic stages of IBD has expanded significantly.

    Investigators have been able to identify biomarkers that may predict IBD, and inflammatory pathways altered many years preceding clinical diagnosis. This means that while we are still far away from finding a preventive strategy for IBD, we are making major advances. Therefore, it is essential that we also start to understand the degree of acceptance that individuals at risk for developing IBD, and parents (in the case of children), would have for undergoing predictive tests and/or preventive treatments.

    As of today, the strongest risk factor for developing IBD is a family history of IBD, especially a first-degree relative (FDR). Therefore, we have developed a survey for persons at risk for IBD, those with an FDR at risk for IBD, or those with an FDR (parent, sibling or child) with IBD.

    Who can Participate? 
    • You are concerned about your child/children developing IBD, because either you and/or your partner have IBD and are either becoming a first-time parent or have an healthy child
    • You are concerned about your healthy child/children developing IBD, because you already have another child/children diagnosed with IBD.
    • You don't have IBD but are concerned about your risk of developing IBD because you have a 1st degree relative diagnosed with IBD (mother, father, sister or brother, or child)
    Your Role in this Study

    This survey will take 10-15min to complete, and the information collected is important for us to understand patient preference and acceptance of potential IBD prevention initiatives.

    Link to survey here:

    This study has been approved by the Hospital Beatriz Ângelo's Research Ethics Board (REB #242/2023_MJH/CMO/NO)

    Primary Contact
    Dr. Joana Torres 

    Principal Investigator
    Dr. Ken Croitoru
    Mount Sinai Hospital, University of Toronto

    Please note: This is a survey developed by Dr Joana Torres and Portugal trying to assess preferences for prediction and prevention of IBD, in collaboration with Dr Ken Croitoru. All data is de-identified and anonymised.
  • What is this study about?

    We want to test if fasting for certain hours daily can help with weight loss and improve gut inflammation. We are asking patients with Crohn’s disease who struggle with weight to participate in this 12-week study.

    Your Role in this Study

    If you join this study, you could be put into two groups. The first group does not fast and eats as usual. The second group is the group that will fast.

    The fasting group fasts for a certain number of hours 6 days a week. They will eat their regular diet during their eating window. They will also meet with a registered dietitian (RD) online. The RD will teach the patient how to fast and help answer questions. The research assistant will call patients every two weeks to discuss changes in medications, disease symptoms and how well the patient is doing with the fasting.

    The other group will be asked to eat their regular diet over the 12-week study. At the end of the study, they will get to meet with the RD and do the fast as well. The research assistant will call patients every two weeks to discuss medication changes and disease symptoms.

    Both groups will complete surveys at the start and end of the study. These surveys will ask about your quality of life and physical activity levels.

    Who can Participate?

    We are recruiting patients who:
    • are located in Calgary, AB or Kelowna, BC;
    • are 18-70 years of age;
    • struggle with their weight;
    • and are affected by Crohn's disease.
    This study has been approved by the University of Calgary's Conjoint Health Research Ethics Board (REB21-1539_REN1).

    Primary Contact
    Munazza Yousuf

    Principal Investigator
    Maitreyi Raman
    University of Calgary
  • What is this study about?

    The purpose of this study is to understand the genetic factors that might be contributing to inflammatory Bowel Disease in individuals of Black or Hispanic/Latinx ancestries. We hope our findings will help in personalizing treatments for IBD.

    Your Role in this Study

    Participants will be asked to:
    • donate one tablespoon of blood and/or saliva sample
    • complete a questionnaire about their IBD history
    • provide access to their medical records
    Who can Participate?

    Participants must:
    • Self-identify as African American or Black or;
    • Self-identify as Hipanic/Latinx;
    • Have been diagnosed with Crohn’s Disease or Ulcerative Colitis;
    • Be willing to donate blood and/or saliva sample;
    • Be willing to give the study access to your medical records.
    All ages are welcome, and participants must have confirmed (via medical records access) IBD. They will also receive compensation for their time after completing all study procedures. The study is located at the Mount Sinai Hospital, Toronto, ON.

    This study has been approved by the Mount Sinai Hospital Research Ethics Board (REB# 02-0234-E).

    Primary Contact

    Principal Investigator
    Mark Silverberg
    Mount Sinai Hospital

  • Canada has among the highest incidence rates of Crohn's and colitis in the world.
  • 1 in 140 Canadians lives with Crohn’s or colitis.
  • Families new to Canada are developing these diseases for the first time.
  • Incidence of Crohn’s in Canadian kids under 10 has doubled since 1995.
  • People are most commonly diagnosed before age 30.

Other Areas of Interest